



PRESS RELEASE
FOR IMMEDIATE RELEASE

8 AUGUST, 2008

TRADE UPDATE FOR 6 MONTHS OF 2008 (UNAUDITED)

8 AUGUST 2008, MOSCOW – OAO Pharmacy Chain 36.6 [RTS: APTK; MICEX: RU14APTK1007] the leading Russian health and beauty retailer announces unaudited sales and operational results according to management accounts.

Group sales:

- Y-o-Y in H1 2008 the Group's consolidated sales increased by 46% and reached US\$ 563.8 million. EMC has been divested in May 2008. The consolidated sales in H1 2008 without EMC amounted US\$ 552.4 million^{*}.

Sales by business unit:

- Sales in the retail unit grew by 50% and reached US\$ 449.7 million.
- Sales of the production unit, Veropharm, reached US\$ 86.5 million (annual growth 49%).
- Sales of other non-core businesses grew by 2.9%, including ELC sales growth of 128.6% (US\$ 2.1 million).

<i>USD mln</i>	Consolidated	Retail	Veropharm	EMC	ELC	Other
H1 2008	563.8	449.7	86.5	11.4	2.1	14.1
H1 2007	385.0	300.0	58.2	12.9	0.9	13.0
<i>Change y-o-y</i>	46.4%	49.9%	48.7%	-11.8%	128.6%	8.7%

Retail:

- As of the end of Q2 2008 Pharmacy Chain 36.6 operates 1 192 stores in 29 regions of Russia.
- During first 6 months of 2008, 38 pharmacies were opened organically, 71 closed, 7 rebranded and 1 reformatted.
- As of the end of Q2 2008 Pharmacy Chain 36.6 operates 10 ELC stores, 14 stand-alone optical outlets with 22 additional optical departments within pharmacies.

H1 2008

Business Unit**	No. of Pharmacies	Share of Sales	Ave. retail space per pharmacy, sq.m.
1. Moscow-Central	402	44.4%	73.4
including Northwest	27	2.6%	84.1
2. South Urals	275	17.5%	56.0
3. South	203	16.0%	50.7
4. Volga	130	8.9%	62.0
5. North Urals	113	8.8%	53.1
6. Siberia	69	4.4%	53.3
<i>Company Total:</i>	1 192	100.0%	61.2

^{*} Hereinafter – these financial indicators may have significant variations from the consolidated data prepared in accordance with IFRS.

^{**} Due to organizational changes Northwest is now managed by Moscow-Central. In addition, Urals is broken into two units North Urals and South Urals.

Operational data for retail unit

- During 6 months of 2008, 53 million purchases were made in Pharmacy Chain 36.6 stores, which is 14% higher than in comparable period of 2007.
- Average check across the network reached USD 8.61, in Moscow USD 11.21 an increase over the comparable period of 18.6% and 9.4% respectively.
- Average sales floor size at the end of Q2 is 61.2 sq meters, a decrease of 2.4% versus 2007.

Like-For-Like sales in comparable stores

As of Q2 2008 the Company will start to provide the following L-F-L sales growth calculation to ensure better transparency on the performance of mature stores.

The L-F-L reporting would be executed for a selection of comparable stores, which are:

- opened or acquired 24 months from the current reporting period, and
- neither rebranded nor reformatted or somehow significantly changed during last 24 months, and
- not closed in the current reporting period.

As of the end of H1 2008 the company operates 406 comparable stores representing 45% of sales and 36% of traffic in the retail unit. The L-F-L sales growth in these stores in H1 2008 reached 16% as compared to H1 2007 while the traffic decreased by 5%:

Business Unit *	Number of comparable stores	L-F-L sales growth	Average check growth
1. Moscow-Central	152	14%	15%
Northwest	19	40%	31%
2. South Urals	120	14%	31%
3. South	32	28%	30%
4. Volga	71	20%	29%
5. North Urals	1	7%	36%
6. Siberia	11	36%	46%
<i>Total:</i>	406	16%	23%

#

For further information please refer to:

Maxim Arkhipov

Director, Corporate finance and investor relations

arkhipov@oao366.ru

tel. (+7495) 797 86 86 ext.1763

Maria Zhog

Manager, corporate communications and investor relations

mzhog@oao366.ru

tel (+7495) 797 86 86 ext.1534

Or to the web-site of the company:

www.pharmacychain366.ru

Notes to the editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of August 7, 2008 totaled USD 304 million (according to RTS). Pharmacy Chain 36.6 operates more than 1100 stores in 29 regions and 90 cities in Russia.

OAO Veropharm, the company's generics subsidiary, is one of Russia's top five manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization as of August 7, 2008 was USD 450 million (according to RTS).

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC). Pharmacy Chain 36.6 is a participating member of the international retailers' organizations - NRF and NACDS. Pharmacy Chain 36.6 and its subsidiaries employ over 12,000 people.

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.